Markets HCW cuts Trillium Therapeutics to neutral and removes PT H.C. Wainwright downgraded Trillium Therapeutics (NASDAQ:TRIL) to “neutral” from “buy” and removed its price target, saying the precipitous fall in the stock price could lead to a cash crunch. Over the last six months... August 19, 2019